2023-06-21 15:44:13 ET
Aethlon Medical ( NASDAQ: AEMD ) said it is investigating using its Hemopurifier device to remove harmful viruses and exosomes from harvested organs, which could help reduce complications associated with organ transplantation.
The medical device developer said that goal would be to position the Hemopurifier as an accessory to current or future organ perfusion systems that are used to keep donated organs in transpantable condition.
More on Aethlon:
- Aethlon Medical GAAP EPS of -$0.12 misses by $0.04
- Aethlon stock soars ~40% on pact for Hemopurifier clinical program in cancer
For further details see:
Aethlon evaluating use of Hemopurifier device in organ transplantation